Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus [Advagraf] + Sirolimus [Rapamune], Versus Extended Release Tacrolimus [Advagraf] + Mycophenolate Mofetil in Kidney Transplant Patients

Trial Profile

Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus [Advagraf] + Sirolimus [Rapamune], Versus Extended Release Tacrolimus [Advagraf] + Mycophenolate Mofetil in Kidney Transplant Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Sirolimus (Primary) ; Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Results published in the Nephrology Dialysis Transplantation
    • 03 May 2017 Results assessing efficacy and safety, presented at the 2017 American Transplant Congress
    • 07 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top